Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas.

Current opinion in oncology - 1 Nov 2018

Friedrich Mirco, Bunse Lukas, Wick Wolfgang, Platten Michael

Abstract excerpt

PURPOSE OF REVIEW: The present review introduces recent progress in eliciting the role of mutant isocitrate dehydrogenase (IDH) in gliomas, especially regarding its mode of action as a modulator of antitumor immune response, and provides rationales for targeting mutant IDH in glioma immunotherapy. Both the development of small molecule inhibitors repressing the enzymatic activity of mutant IDH and novel,...

Topics

Join the communities discussing this publication.

Brain Neoplasms
Glioma
Immunotherapy
Isocitrate Dehydrogenase
Mutation
Tumor Escape

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30102604
DOI: 10.1097/CCO.0000000000000478

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas.PMID 30102604Read ↗

Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma.Semantic proximity Read ↗

Therapies for IDH-Mutant Gliomas.Semantic proximity Read ↗

Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis.Semantic proximity Read ↗

Implications of IDH mutations on immunotherapeutic strategies for malignant glioma.Semantic proximity Read ↗

Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade GliomaSemantic proximity Read ↗

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.Semantic proximity Read ↗

Targeting IDH1/IDH2 mutations in gliomas.Semantic proximity Read ↗

IDH mutation in glioma: molecular mechanisms and potential therapeutic targets.Semantic proximity Read ↗

Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors.Semantic proximity Read ↗

Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas.Semantic proximity Read ↗

IDH mutation in glioma: new insights and promises for the future.Semantic proximity Read ↗

IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical ImplicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.